Ignite Creation Date:
2024-05-06 @ 3:39 AM
Last Modification Date:
2024-10-26 @ 11:37 AM
Study NCT ID:
NCT02349724
Status:
UNKNOWN
Last Update Posted:
2017-04-25
First Post:
2015-01-25
Brief Title:
A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
Sponsor:
Southwest Hospital China
Organization:
Southwest Hospital China
Study Overview
Official Title:
A Clinical Research of Chimeric Antigen ReceptorCAR T Cells Targeting CEA Positive Cancer
Status:
UNKNOWN
Status Verified Date:
2016-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this research is to verify the safety of CEA targeted chimeric antigen receptor T cells and to determine the proper dosage of CAR T cells infused
Detailed Description:
Chimeric antigen receptor CAR-modified T cells have demonstrated great successes in treating even late stage cluster of differentiation antigen 19 CD19 positive B cell malignancies But it has not yet been fully explored in solid tumors The carcino-embryonic antigenCEA is widely expressed in cancers like gastric cancer lung cancer pancreatic cancer breast cancer and colorectal cancer To confirm if CAR T cells still function in solid tumors we have developed anti-CEA CAR-modified T cells Preclinical studies have demonstrated effective killing of CEA target cells In this study the CEA CARs will be evaluated in CEA positive gastric cancer lung cancer pancreatic cancer breast cancer and colorectal cancer patients The primary goal is to confirm its adverse effects including cytokine storm response and any other adverse effects In addition tumor targeting and disease status after treatment will also be evaluated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None